[HTML][HTML] Molecular changes in chronic myeloid leukemia during tyrosine kinase inhibitors treatment. focus on immunological pathways
M Janowski, Z Ulańczyk, K Łuczkowska… - OncoTargets and …, 2022 - ncbi.nlm.nih.gov
Methods Global gene and miRNA expression profiles were assessed using genome-wide
RNA and miRNA microarray technology in bone marrow mononuclear cells. Fifty-one …
RNA and miRNA microarray technology in bone marrow mononuclear cells. Fifty-one …
Molecular Changes in Chronic Myeloid Leukemia During Tyrosine Kinase Inhibitors Treatment. Focus on Immunological Pathways.
M Janowski, Z Ulańczyk, K Łuczkowska… - Oncotargets and …, 2022 - europepmc.org
Methods Global gene and miRNA expression profiles were assessed using genome-wide
RNA and miRNA microarray technology in bone marrow mononuclear cells. Fifty-one …
RNA and miRNA microarray technology in bone marrow mononuclear cells. Fifty-one …
Molecular Changes in Chronic Myeloid Leukemia During Tyrosine Kinase Inhibitors Treatment. Focus on Immunological Pathways.
M Janowski, Z Ulańczyk, K Łuczkowska… - OncoTargets & …, 2022 - search.ebscohost.com
Introduction: The aim of our research was to investigate changes in the molecular
background of the immune response in the chronic phase (CP) of chronic myeloid …
background of the immune response in the chronic phase (CP) of chronic myeloid …
Molecular Changes in Chronic Myeloid Leukemia During Tyrosine Kinase Inhibitors Treatment. Focus on Immunological Pathways
M Janowski, Z Ulańczyk, K Łuczkowska… - OncoTargets and …, 2022 - search.proquest.com
Introduction: The aim of our research was to investigate changes in the molecular
background of the immune response in the chronic phase (CP) of chronic myeloid …
background of the immune response in the chronic phase (CP) of chronic myeloid …
Molecular Changes in Chronic Myeloid Leukemia During Tyrosine Kinase Inhibitors Treatment. Focus on Immunological Pathways
M Janowski, Z Ulańczyk… - OncoTargets and …, 2022 - pubmed.ncbi.nlm.nih.gov
Introduction The aim of our research was to investigate changes in the molecular
background of the immune response in the chronic phase (CP) of chronic myeloid …
background of the immune response in the chronic phase (CP) of chronic myeloid …
Molecular Changes in Chronic Myeloid Leukemia During Tyrosine Kinase Inhibitors Treatment. Focus on Immunological Pathways
M Janowski, Z Ulańczyk, K Łuczkowska… - OncoTargets and …, 2022 - dovepress.com
Methods: Global gene and miRNA expression profiles were assessed using genome-wide
RNA and miRNA microarray technology in bone marrow mononuclear cells. Fifty-one …
RNA and miRNA microarray technology in bone marrow mononuclear cells. Fifty-one …
[PDF][PDF] Molecular Changes in Chronic Myeloid Leukemia During Tyrosine Kinase Inhibitors Treatment. Focus on Immunological Pathways
M Janowski, Z Ulańczyk, K Łuczkowska… - OncoTargets and …, 2022 - scienceopen.com
Discussion: Upregulated biological processes according to gene ontology (GO)
classification involved basic cellular processes such as cell division, cell cycle, cell–cell …
classification involved basic cellular processes such as cell division, cell cycle, cell–cell …
Molecular Changes in Chronic Myeloid Leukemia During Tyrosine Kinase Inhibitors Treatment. Focus on Immunological Pathways.
M Janowski, Z Ulańczyk, K Łuczkowska… - Oncotargets and …, 2022 - europepmc.org
Methods Global gene and miRNA expression profiles were assessed using genome-wide
RNA and miRNA microarray technology in bone marrow mononuclear cells. Fifty-one …
RNA and miRNA microarray technology in bone marrow mononuclear cells. Fifty-one …